Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer



Status:Recruiting
Conditions:Ovarian Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:May 18, 2016

Use our guide to learn which trials are right for you!

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This phase I/II partially randomized trial studies the side effects and the best dose of
ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well
they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or
primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better
treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer.

PRIMARY OBJECTIVES:

I. Determine whether treatment with ruxolitinib in combination with conventional neoadjuvant
and post-surgical chemotherapy is safe and tolerable in the primary therapy for epithelial
ovarian, fallopian tube, or primary peritoneal carcinoma. (Phase I) II. Demonstrate whether
treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical
chemotherapy results in a prolonged progression-free survival when compared to chemotherapy
alone, in primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal
carcinoma. (Phase II)

SECONDARY OBJECTIVES:

I. Determine frequency of patients who do not receive surgery within 6 weeks of completing
cycle 3 therapy for reasons other than non-response, disease progression, or medical
contraindications. (Phase I) II. Determine if continuation of ruxolitinib as maintenance
therapy in participants who complete 6 cycles of standard chemotherapy in combination with
ruxolitinib and have not experienced unacceptable toxicity or disease progression is safe and
tolerable. (Phase I) III. Determine the impact of ruxolitinib in combination with
chemotherapy on progression-free survival as a function of proposed exploratory biomarkers -
ALDH+ CD133+ (possibly also CD24+ CK19+) co-staining by AQUA immunofluorescence (IF); ratio
of tumor expression of CD8:FOXP3 by immunohistochemistry (IHC); and tumor CD3, CD4, TAI-1,
HLA class I and II, CD68 expression by IHC in archived tumor tissue and serum C-reactive
protein (CRP) and IL-6 levels in pre-treatment serum. (Phase II) IV. Investigate the
prognostic significance of exploratory laboratory parameters in terms of both
progression-free survival and overall survival in women receiving conventional chemotherapy
alone. (Phase II) V. Determine whether treatment with ruxolitinib in combination with
conventional chemotherapy is associated with total gross resection rate at time of interval
cytoreductive surgery. (Phase II) VI. Determine whether treatment with ruxolitinib in
combination with conventional chemotherapy is associated with complete pathologic response
defined at interval cytoreductive surgery. (Phase II) VII. Demonstrate whether treatment with
ruxolitinib in combination with conventional chemotherapy results in an improvement in
overall survival in primary management of epithelial ovarian, fallopian tube, or primary
peritoneal carcinoma. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of ruxolitinib phosphate, followed by a
phase II study.

PHASE I PORTION OF STUDY IS COMPLETE (04/06/2018)

PHASE I (COURSES 1-3): Patients receive ruxolitinib phosphate orally (PO) twice daily (BID)
on days 1-21, paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15, and carboplatin
IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of
disease progression or unacceptable toxicity. Within 6 weeks after completion of course 3,
patients undergo tumor reductive surgery (TRS).

PHASE I (COURSES 4-6): Within 6 weeks of TRS, patients receive ruxolitinib phosphate PO BID
on days 1-21, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30
minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease
progression or unacceptable toxicity. If TRS is not performed due to non-response or medical
contraindications and criteria for discontinuation of protocol therapy have not been met,
patients should resume ruxolitinib phosphate, paclitaxel, and carboplatin within 6 weeks of
completing course 3 of therapy.

MAINTENANCE THERAPY: Within 3 weeks after completion of course 6, patients receive
ruxolitinib phosphate PO BID. Treatment continues in the absence of disease progression or
unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I (COURSES 1-3): Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and
carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the
absence of disease progression or unacceptable toxicity. Patients then undergo TRS.

ARM I (COURSES 4-6): Within 4 weeks of surgery (within 6 weeks of completion of course 3 in
patients who do not undergo TRS), patients receive paclitaxel IV over 1 hour on days 1, 8,
and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3
courses in the absence of disease progression or unacceptable toxicity.

ARM II (COURSES 1-3): Patients receive ruxolitinib phosphate PO BID on days 1-21 and
paclitaxel and carboplatin as in arm I. Treatment repeats every 21 days for 3 courses in the
absence of disease progression or unacceptable toxicity. Patients then undergo TRS.

ARM II (COURSES 4-6): Within 4 weeks of surgery (within 6 weeks of completion of course 3 in
patients who do not undergo TRS), patients receive ruxolitinib phosphate PO BID on days 1-21
and paclitaxel and carboplatin as in arm I. Treatment repeats every 21 days for 3 courses in
the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients in phase I are followed up until resolution of
adverse events, and patients in phase II are followed up every 3 months for 2 years and then
every 6 months for 3 years.

Inclusion Criteria:

- Patients must have clinically and radiographically suspected and previously untreated
International Federation of Gynecologic and Obstetrics (FIGO) stage III or IV
epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom
the plan of management will include neoadjuvant chemotherapy (NACT) with interval
tumor reductive surgery (TRS) who have undergone biopsies for histologic confirmation

- Institutional confirmation of Mullerian epithelial adenocarcinoma on core biopsy (not
cytology or fine needle aspiration) or laparoscopic biopsy; (for phase II of the study
formalin-fixed paraffin-embedded [FFPE] tissue should be available for laboratory
analysis); patients with the following histologic epithelial cell types are eligible:
high grade serous carcinoma, high grade endometrioid carcinoma, clear cell carcinoma,
or a combination of these

- All patients must have measurable disease as defined by Response Evaluation Criteria
In Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one lesion
that can be accurately measured in at least one dimension (longest diameter to be
recorded); each lesion must be >= 10 mm when measured by computed tomography (CT),
magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm
when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured
by CT or MRI

- Appropriate stage for study entry based on the following diagnostic workup:

- History/physical examination within 28 days prior to registration

- Radiographic imaging of the chest, abdomen and pelvis within 28 days prior to
registration documenting disease consistent with FIGO stage III or IV disease

- Further protocol-specific assessments

- Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status of 0, 1, or 2
within 28 days prior to registration

- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl; this ANC cannot
have been induced by granulocyte colony stimulating factors (within 14 days prior to
registration)

- Platelets greater than or equal to 100,000/mcl (within 14 days prior to registration)

- Hemoglobin greater than 9.0 mg/dl (transfusions are permitted to achieve baseline
hemoglobin level) (within 14 days prior to registration)

- Estimated creatinine clearance (CrCl) >= 50 mL/min/1.73 m^2 according to the
Cockcroft-Gault formula (within 14 days prior to registration)

- Bilirubin =< 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (within
14 days prior to registration)

- Alkaline phosphatase =< 2.5 x ULN (within 14 days prior to registration)

- Neurologic function: neuropathy (sensory and motor) less than or equal to Common
Terminology Criteria for Adverse Events (CTCAE) grade 1

- Ability to swallow and retain oral medication

- The patient must provide study-specific informed consent prior to study entry

Exclusion Criteria:

- Patients with suspected non-gynecologic malignancy, such as gastrointestinal

- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer and other specific malignancies are excluded if there is any
evidence of other malignancy being present within the last three years (2 years for
breast cancer); patients are also excluded if their previous cancer treatment
contraindicates this protocol therapy

- Patients who have received prior chemotherapy for any abdominal or pelvic tumor within
the last three years are excluded; patients may have received prior adjuvant
chemotherapy and radiotherapy for localized breast cancer, provided that it was
completed more than 2 years prior to registration, the patient remains free of
recurrent or metastatic disease and hormonal therapy has been discontinued

- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis or thoracic cavity within the last three years are excluded; prior radiation
for localized cancer of the head and neck or skin is permitted, provided that it was
completed more than three years prior to registration, and the patient remains free of
recurrent or metastatic disease

- Patients who have received any targeted therapy (including but not limited to
vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management
of their epithelial ovarian, fallopian tube or peritoneal primary cancer

- Patients with mucinous carcinoma, low grade endometrioid carcinoma, low grade serous
carcinoma or carcinosarcoma

- Patients with synchronous primary endometrial cancer, or a past history of primary
endometrial cancer, unless all of the following conditions are met: stage not greater
than I-A, grade 1 or 2, no more than superficial myometrial invasion, without vascular
or lymphatic invasion; no poorly differentiated subtypes, including serous, clear cell
or other FIGO grade 3 lesions

- Severe, active co-morbidity defined as follows:

- Chronic or current active infectious disease requiring systemic antibiotics,
antifungal or antiviral treatment

- Known brain or central nervous system metastases or history of uncontrolled
seizures

- Clinically significant cardiac disease including unstable angina, acute
myocardial infarction within 6 months from enrollment, New York Heart Association
class III or IV congestive heart failure, and serious arrhythmia requiring
medication (this does not include asymptomatic atrial fibrillation with
controlled ventricular rate)

- Partial or complete gastrointestinal obstruction

- Patients who are not candidates for major abdominal surgery due to known medical
comorbidities

- Patients with any condition that in the judgment of the investigator would jeopardize
safety or patient compliance with the protocol

- Patients who are unwilling to be transfused with blood components

- Concurrent anticancer therapy (e.g. chemotherapy, radiation therapy, biologic therapy,
immunotherapy, hormonal therapy, investigational therapy)

- Receipt of an investigational study drug for any indication within 30 days or 5
half-lives (whichever is longer) prior to day 1 of protocol therapy

- Patients who, in the opinion of the investigator, are unable or unlikely to comply
with the dosing schedule and study evaluations

- Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must
agree to use adequate contraception (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation; WOCBP
must have a screening negative serum or urine pregnancy test within 14 days of
registration; a second pregnancy test must be done within 24 hours prior to the start
of the first cycle of study treatment; women must not be breastfeeding

- Women who are not of childbearing potential (i.e., who are postmenopausal or
surgically sterile) do not require contraception

- Women of childbearing potential (WOCBP) is defined as any female who has
experienced menarche and who has not undergone surgical sterilization
(hysterectomy and/or bilateral oophorectomy) or who is not postmenopausal;
menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the
absence of other biological or physiological causes; in addition, women under the
age of 55 must have a documented serum follicle stimulating hormone (FSH) level
greater than 40mIU/mL

- Known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
infection or known history of tuberculosis
We found this trial at
63
sites
6401 France Ave S
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
?
mi
from
Edina, MN
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Carolyn Y. Muller
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Shashikant B. Lele
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Charles N. Landen
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Carolyn Y. Muller
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Guilherme Henrique C. Cantuaria
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
?
mi
from
Augusta, GA
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Deborah K. Armstrong
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
3110 MacCorkle Avenue Southeast
Charleston, West Virginia 25304
Principal Investigator: Steven J. Jubelirer
Phone: 304-388-9944
?
mi
from
Charleston, WV
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: John W. Moroney
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Edward J. Tanner
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3535 Olentangy River Rd
Columbus, Ohio 43214
(614) 566-5000
Principal Investigator: Timothy D. Moore
Phone: 614-566-4475
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3100 Plaza Properties Blvd
Columbus, Ohio 43219
(614) 383-6000
Principal Investigator: Timothy D. Moore
Phone: 614-488-2118
The Mark H. Zangmeister Center At The Zangmeister Center, we appreciate that our patients have...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Covington, Louisiana 70433
Principal Investigator: Patricia S. Braly
Phone: 412-339-5294
?
mi
from
Covington, LA
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: David S. Miller
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Principal Investigator: David S. Miller
Phone: 214-590-5582
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: Georgina Cheng
Phone: 800-446-5532
?
mi
from
Danville, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Georgina Cheng
Phone: 800-446-5532
?
mi
from
Effingham, IL
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Donna M. McNamara
Phone: 201-996-2879
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: Michael J. Callahan
Phone: 317-338-2194
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: David P. Bender
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Mary E. Gordinier
Phone: 502-629-2500
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Louisville, Kentucky 40207
Principal Investigator: Mary E. Gordinier
Phone: 502-629-3465
?
mi
from
Louisville, KY
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Lisa M. Barroilhet
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Maple Grove, Minnesota 55369
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
?
mi
from
Maple Grove, MN
Click here to add this to my saved trials
Mattoon, Illinois 61938
Principal Investigator: Georgina Cheng
Phone: 800-446-5532
?
mi
from
Mattoon, IL
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
Principal Investigator: Peter G. Rose
Phone: 866-223-8100
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: William H. Bradley
Phone: 414-805-4380
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
800 E 28th St
Minneapolis, Minnesota 55407
(612) 863-4000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Abbott Northwestern Hospital Our hospital has a long and proud history as a health care...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Alaina J. Brown
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Katrina S. Wade
Phone: 504-703-8712
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Katherine M. Moxley
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Principal Investigator: Brent J. Tierney
Phone: 402-354-5144
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orland Park, Illinois 60462
Principal Investigator: John W. Moroney
Phone: 773-702-8222
?
mi
from
Orland Park, IL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Robert A. Burger
Phone: 800-474-9892
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Alexander B. Olawaiye
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
1015 NW 22nd Ave
Portland, Oregon 97210
(503) 413-7711
Principal Investigator: Colleen C. McCormick
Phone: 800-220-4937
Legacy Good Samaritan Hospital and Medical Center Located in the heart of Northwest Portland, Legacy...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Providence, Rhode Island 02905
Principal Investigator: Cara A. Mathews
Phone: 401-274-1122
?
mi
from
Providence, RI
Click here to add this to my saved trials
Rio Rancho, New Mexico 87124
Principal Investigator: Carolyn Y. Muller
Phone: 505-559-6113
?
mi
from
Rio Rancho, NM
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
3850 Park Nicollet Blvd
Saint Louis Park, Minnesota 55416
(952) 993-3123
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Park Nicollet Clinic - Saint Louis Park Park Nicollet Health Services is a nonprofit, integrated...
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
640 Jackson Street
Saint Paul, Minnesota 55101
651-254-3456
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
Regions Hospital Established in 1872, Regions Hospital is a private, not-for-profit organization. The hospital provides...
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
333 Smith Ave
Saint Paul, Minnesota 55102
(651) 241-8000
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
United Hospital United Hospital is the largest hospital in the Twin Cities east metro area,...
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
1700 S Tamiami Trail
Sarasota, Florida 34239
(941) 917-9000
Sarasota Memorial Hospital Sarasota Memorial Health Care System, an 806-bed regional medical center, is among...
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
Savannah, Georgia 31405
Principal Investigator: Howard A. Zaren
Phone: 412-339-5294
?
mi
from
Savannah, GA
Click here to add this to my saved trials
225 Candler Drive
Savannah, Georgia 31405
Principal Investigator: Howard A. Zaren
Phone: 412-339-5294
?
mi
from
Savannah, GA
Click here to add this to my saved trials
4700 Waters Ave
Savannah, Georgia 31404
(912) 350-8000
Principal Investigator: James J. Burke
Phone: 912-350-7887
Memorial Health University Medical Center Memorial University Medical Center (MUMC) is a nonprofit, 622-bed tertiary...
?
mi
from
Savannah, GA
Click here to add this to my saved trials
1235 E Cherokee St
Springfield, Missouri 65804
(417) 820-2000
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Mercy Hospital Springfield We're continuing a tradition of healing more than 120 years old. Mercy...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
3801 South National Avenue
Springfield, Missouri 65807
(417) 269-6000
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
CoxHealth South Hospital U.S. News & World Report has ranked CoxHealth one of Missouri's best...
?
mi
from
Springfield, MO
Click here to add this to my saved trials
105 Sixth St
Traverse City, Michigan 49684
(231) 935-5000
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Munson Medical Center There’s no place quite like northern Michigan, and there is no other...
?
mi
from
Traverse City, MI
Click here to add this to my saved trials
19300 SW 65th Ave
Tualatin, Oregon 97062
(503) 692-1212
Principal Investigator: Colleen C. McCormick
Phone: 503-413-1742
Legacy Meridian Park Hospital Legacy Meridian Park Medical Center opened its new Chest Pain Center,...
?
mi
from
Tualatin, OR
Click here to add this to my saved trials
Urbana, Illinois 61801
Principal Investigator: Georgina Cheng
Phone: 800-446-5532
?
mi
from
Urbana, IL
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Principal Investigator: Georgina Cheng
Phone: 800-446-5532
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Vancouver, Washington 98686
Principal Investigator: Colleen C. McCormick
Phone: 503-413-2150
?
mi
from
Vancouver, WA
Click here to add this to my saved trials
3941 Commerce Avenue
Willow Grove, Pennsylvania 19090
Principal Investigator: Mark S. Shahin
Phone: 215-481-2402
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Woodbury, Minnesota 55125
Principal Investigator: Jessica A. Thomes Pepin
Phone: 952-993-1517
?
mi
from
Woodbury, MN
Click here to add this to my saved trials